Vern Norviel

Building the future of personalized medicine for patients with genetic diseases.

Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We have developed a patented macrophage-targeted technology, NP001, that addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS. NP001 has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are working to move this compound toward approval and delivering an effective and safe new treatment for ALS.

Cancer Commons is a patient-centric nonprofit that features compassionate experts who build relationships with advanced cancer patients and caregivers to create personalized action plans. Our nurse navigators, PhD scientists, and national experts consult the latest, most-promising research to identify, explain, and help patients access their best-possible diagnostic and treatment options—so everyone feels confident they’ve left no stone unturned.

Established in 2017, the Healthcare Innovation and Design Program prepares students, faculty, and the community to apply design thinking and entrepreneurial skills to solve some of the 21st century’s most pressing healthcare challenges. The Program partners with bioengineering companies and medical organizations to provide real-world projects, internships, and value-driven partnerships that engage interdisciplinary teams of engineers, scientists, and business experts.

Building the future of personalized medicine for patients with genetic diseases.

An Oral Cancer Screening Company.

Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We have developed a patented macrophage-targeted technology, NP001, that addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS. NP001 has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are working to move this compound toward approval and delivering an effective and safe new treatment for ALS.

Cancer Commons is a patient-centric nonprofit that features compassionate experts who build relationships with advanced cancer patients and caregivers to create personalized action plans. Our nurse navigators, PhD scientists, and national experts consult the latest, most-promising research to identify, explain, and help patients access their best-possible diagnostic and treatment options—so everyone feels confident they’ve left no stone unturned.

Morris Animal Foundation is a global leader in advancing veterinary medicine through science. Since 1948, we’ve invested nearly $170 million in over 3,100 studies to improve the health and quality of life for dogs, cats, horses, and wildlife worldwide. Our funded research has led to breakthroughs in prevention, diagnostics, treatment, and cures — many now considered gold standards in veterinary care. From developing vaccines and surgical techniques to identifying genetic risk factors and environmental threats, our work powers progress across all areas of animal health. Our rigorous, competitive grants process ensures donor dollars fund the most promising, high-impact studies. Researchers we support are tackling some of the toughest challenges in animal health — cancer, infectious disease, pain management, aging, and more. At Morris Animal Foundation, we believe animals deserve longer, healthier lives. That’s why we fund the science that makes it possible. 🔬 Learn more: www.morrisanimalfoundation.org